secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-06-17T12:03:10+00:00
Accession:  0001601485-26-000048
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC
--------------------------------------------------------------------------------

- 100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.
- Complete responses rarely observed (0-8%) in metastatic pancreatic cancer; all 3 patients are MSS/MMR-p, historically refractory to immunotherapy.
- Two patients maintained complete responses ≥8 months; one ongoing >13 months with persistent mKRAS-specific T cells.
- Elicio plans Phase 1 study in first-line metastatic mKRAS PDAC combining ELI-002 7P with chemotherapy and anti-PD-1, subject to funding.
- Virtual KOL event June 24, 2026, to discuss observations with UCLA and University of Miami oncologists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/0001601485-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000048/angn-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001601485-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer